Literature DB >> 21464870

Prolonged neutropenia after neoadjuvant radiation therapy and chemotherapy using oxaliplatin and capecitabine for rectal cancer.

Daniel C McFarland, William T Leslie.   

Abstract

Entities:  

Year:  2011        PMID： 21464870      PMCID： PMC3070280     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  10 in total

1.  Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

Authors:  David P Ryan; Donna Niedzwiecki; Donna Hollis; Brent E Mediema; Scott Wadler; Joel E Tepper; Richard M Goldberg; Robert J Mayer
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

2.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

4.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Authors:  Carlo Aschele; Luca Cionini; Sara Lonardi; Carmine Pinto; Stefano Cordio; Gerardo Rosati; Salvatore Artale; Angiolo Tagliagambe; Giovanni Ambrosini; Paola Rosetti; Andrea Bonetti; Maria Emanuela Negru; Maria Chiara Tronconi; Gabriele Luppi; Giovanni Silvano; Domenico Cristiano Corsi; Anna Maria Bochicchio; Germana Chiaulon; Maurizio Gallo; Luca Boni
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

5.  In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line.

Authors:  Johan Kjellström; Elisabeth Kjellén; Anders Johnsson
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

6.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

7.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 8.  Radiation therapy in stage II and III rectal cancer.

Authors:  Christopher G Willett; Brian G Czito; Johanna C Bendell
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

Review 9.  Combining radiation with oxaliplatin: a review of experimental results.

Authors:  R M Hermann; M Rave-Fränk; O Pradier
Journal:  Cancer Radiother       Date:  2008-02-20       Impact factor: 1.018

Review 10.  Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.

Authors:  Andrew X Zhu; Christopher G Willett
Journal:  Semin Radiat Oncol       Date:  2003-10       Impact factor: 5.934
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.